Ipca Laboratories
| Company type | Public |
|---|---|
| BSE: 524494 NSE: IPCALAB | |
| Industry | Pharmaceutical |
| Founded | 19 October 1949 as The Indian Pharmaceutical Combine Association Limited |
| Founder | K.B. Mehla Dr. N.S. Tibrawala |
| Headquarters | Mumbai, Maharashtra, India |
Area served | Worldwide |
Key people | Premchand Godha (MD) AK Jain (JMD) |
| Products | Pharmaceutical drugs, generic drugs, antiviral drugs, over-the-counter drugs, vaccines, |
| Revenue | ₹9,032 crore (US$1.1 billion) (2025) |
| ₹1,336 crore (US$160 million) (2025) | |
| ₹785 crore (US$93 million) (2025) | |
Number of employees | 18,043 (2025) |
| Subsidiaries | CCPL Software, Ipca Traditional Remedies |
| Website | www |
| Footnotes / references Financials as of 31 March 2025. | |
Ipca Laboratories Limited is an Indian multinational pharmaceutical company based in Mumbai. It produces theobromine, acetylthiophene, and p-bromotoluene as active pharmaceutical ingredients (APIs). Ipca sells these APIs and their intermediates globally. It produces more than 150 formulations that include oral liquids, tablets, dry powders, and capsules.